ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.56) by 32.14 percent. The company reported quarterly sales of $18.053 million which missed the analyst consensus estimate of $18.102 million by 0.27 percent. This is a 4.94 percent decrease over sales of $18.992 million the same period last year.
ADC Therapeutics Q1 2024 Adj EPS $(0.38) Beats $(0.56) Estimate, Sales $18.053M Miss $18.102M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.